Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center
News Jan 09, 2009
Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky.
Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.
The vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo immune response to multiple oncology related targets. The vaccine scaffold can be customized for various clinical indications and represents a major advance for immunotherapy.
A Phase I clinical trial is scheduled to start early in 2009.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018